KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Change in Receivables: 2018-2024

Historic Change in Receivables for Castle Biosciences (CSTL) over the last 7 years, with Dec 2024 value amounting to $12.6 million.

  • Castle Biosciences' Change in Receivables fell 144.92% to -$1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $165,000, marking a year-over-year decrease of 98.73%. This contributed to the annual value of $12.6 million for FY2024, which is 15.32% down from last year.
  • Castle Biosciences' Change in Receivables amounted to $12.6 million in FY2024, which was down 15.32% from $14.9 million recorded in FY2023.
  • In the past 5 years, Castle Biosciences' Change in Receivables ranged from a high of $14.9 million in FY2023 and a low of -$1.7 million during FY2020.
  • In the last 3 years, Castle Biosciences' Change in Receivables had a median value of $12.6 million in 2024 and averaged $11.3 million.
  • As far as peak fluctuations go, Castle Biosciences' Change in Receivables slumped by 285.60% in 2020, and later surged by 378.47% in 2021.
  • Castle Biosciences' Change in Receivables (Yearly) stood at -$1.7 million in 2020, then surged by 378.47% to $4.6 million in 2021, then soared by 34.27% to $6.2 million in 2022, then surged by 140.11% to $14.9 million in 2023, then dropped by 15.32% to $12.6 million in 2024.